{"id":64256,"date":"2026-04-29T22:05:08","date_gmt":"2026-04-29T14:05:08","guid":{"rendered":"https:\/\/flcube.com\/?p=64256"},"modified":"2026-04-29T22:05:09","modified_gmt":"2026-04-29T14:05:09","slug":"fosun-pharma-reports-strong-q1-2026-results-with-22-profit-growth-and-robust-pipeline-advancement","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64256","title":{"rendered":"Fosun Pharma Reports Strong Q1 2026 Results with 22% Profit Growth and Robust Pipeline Advancement"},"content":{"rendered":"\n<p><strong>Shanghai Fosun Pharmaceutical (Group) Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600196:SHA\">SHA: 600196<\/a>; <a href=\"https:\/\/www.google.com\/finance\/quote\/2196:HKG\">HKG: 2196<\/a>) reported <strong>Q1 2026 financial results<\/strong> showing <strong>RMB 10.073 billion<\/strong> (<strong>USD 1.47 billion<\/strong>) in revenue, representing <strong>6.93% year-over-year (YOY) growth<\/strong>, while <strong>net profit attributable to shareholders<\/strong> (excluding non-recurring items) surged <strong>21.96% YOY to RMB 501 million<\/strong> (<strong>USD 73.3 million<\/strong>).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-performance-summary\">Financial Performance Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Q1 2026<\/th><th>YOY Change<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Revenue<\/strong><\/td><td>RMB 10.073B (USD 1.47B)<\/td><td>+6.93%<\/td><\/tr><tr><td><strong>R&amp;D Expenses<\/strong><\/td><td>RMB 897M (USD 131M)<\/td><td>Increased investment<\/td><\/tr><tr><td><strong>Net Profit<\/strong> (core operations)<\/td><td>RMB 501M (USD 73.3M)<\/td><td>+21.96%<\/td><\/tr><tr><td><strong>Profit Margin Expansion<\/strong><\/td><td>Notable improvement<\/td><td>Driven by operational efficiency<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pipeline-amp-regulatory-milestones\">Pipeline &amp; Regulatory Milestones<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-marketing-applications\">Marketing Applications<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>4 innovative drug marketing applications<\/strong> accepted for review by <strong>China NMPA<\/strong> or <strong>U.S. FDA<\/strong><\/li>\n\n\n\n<li>Focus on core therapeutic areas including <strong>oncology<\/strong><\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-clinical-trial-approvals\">Clinical Trial Approvals<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>14 innovative drug clinical trial approvals<\/strong> received from domestic and overseas regulatory authorities<\/li>\n\n\n\n<li>Demonstrates robust pipeline progression across multiple geographies<\/li>\n\n\n\n<li>Oncology remains primary therapeutic focus area<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-global-commercial-expansion\">Global Commercial Expansion<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-product-registration-progress\">Product Registration Progress<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Denosumab<\/strong> and <strong>bevacizumab<\/strong> overseas registrations advancing steadily<\/li>\n\n\n\n<li>Expanding international product portfolio beyond Chinese markets<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-strategic-partnerships\">Strategic Partnerships<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Deepened collaborations<\/strong> with global partners including <strong>Eisai<\/strong> and <strong>Abbott<\/strong><\/li>\n\n\n\n<li><strong>Geographic Coverage:<\/strong> Accelerated market penetration in <strong>Japan<\/strong>, <strong>Asia-Pacific<\/strong>, <strong>Middle East<\/strong>, <strong>Africa<\/strong>, and <strong>Eastern Europe<\/strong><\/li>\n\n\n\n<li><strong>Commercial Network:<\/strong> Continued expansion of global regulatory and commercial infrastructure<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-investment-amp-innovation-focus\">Strategic Investment &amp; Innovation Focus<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>R&amp;D Commitment:<\/strong> Sustained investment at RMB 897 million reflects dedication to innovation-driven growth<\/li>\n\n\n\n<li><strong>Pipeline Diversification:<\/strong> Balanced approach across oncology and other therapeutic areas<\/li>\n\n\n\n<li><strong>Global Strategy:<\/strong> Leveraging partnerships to accelerate international commercial success<\/li>\n\n\n\n<li><strong>Operational Efficiency:<\/strong> Strong profit growth outpacing revenue growth indicates improved operational leverage<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-positioning\">Market Context &amp; Competitive Positioning<\/h2>\n\n\n\n<p>Fosun Pharma&#8217;s Q1 performance demonstrates successful execution of its <strong>dual strategy<\/strong> of <strong>domestic innovation leadership<\/strong> and <strong>global commercial expansion<\/strong>. The company&#8217;s ability to simultaneously advance multiple regulatory submissions while expanding international partnerships positions it as a leading Chinese pharmaceutical company with genuine global ambitions.<\/p>\n\n\n\n<p>The <strong>22% profit growth<\/strong> significantly outpacing <strong>7% revenue growth<\/strong> suggests effective cost management and margin optimization, while the <strong>robust pipeline activity<\/strong> indicates sustained innovation momentum despite challenging market conditions.<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding financial performance, regulatory approvals, and strategic initiatives. Actual results may differ due to risks including regulatory outcomes, market competition, and global economic conditions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/H2_AN202604281821668903_1.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of H2_AN202604281821668903_1.\"><\/object><a id=\"wp-block-file--media-7179bac5-a31e-4de5-b8c1-0de183f9abae\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/H2_AN202604281821668903_1.pdf\">H2_AN202604281821668903_1<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/H2_AN202604281821668903_1.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-7179bac5-a31e-4de5-b8c1-0de183f9abae\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196; HKG: 2196) reported Q1 2026 financial results&#8230;<\/p>\n","protected":false},"author":1,"featured_media":64258,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,159,893,892],"class_list":["post-64256","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-fosun-pharmaceutical","tag-hkg-2196","tag-sha-600196"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Fosun Pharma Reports Strong Q1 2026 Results with 22% Profit Growth and Robust Pipeline Advancement - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196; HKG: 2196) reported Q1 2026 financial results showing RMB 10.073 billion (USD 1.47 billion) in revenue, representing 6.93% year-over-year (YOY) growth, while net profit attributable to shareholders (excluding non-recurring items) surged 21.96% YOY to RMB 501 million (USD 73.3 million).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64256\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fosun Pharma Reports Strong Q1 2026 Results with 22% Profit Growth and Robust Pipeline Advancement\" \/>\n<meta property=\"og:description\" content=\"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196; HKG: 2196) reported Q1 2026 financial results showing RMB 10.073 billion (USD 1.47 billion) in revenue, representing 6.93% year-over-year (YOY) growth, while net profit attributable to shareholders (excluding non-recurring items) surged 21.96% YOY to RMB 501 million (USD 73.3 million).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64256\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-29T14:05:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-29T14:05:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2908.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64256#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64256\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Fosun Pharma Reports Strong Q1 2026 Results with 22% Profit Growth and Robust Pipeline Advancement\",\"datePublished\":\"2026-04-29T14:05:08+00:00\",\"dateModified\":\"2026-04-29T14:05:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64256\"},\"wordCount\":368,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64256#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2908.webp\",\"keywords\":[\"Finanical Reports\",\"Fosun Pharmaceutical\",\"HKG: 2196\",\"SHA: 600196\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64256#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64256\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64256\",\"name\":\"Fosun Pharma Reports Strong Q1 2026 Results with 22% Profit Growth and Robust Pipeline Advancement - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64256#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64256#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2908.webp\",\"datePublished\":\"2026-04-29T14:05:08+00:00\",\"dateModified\":\"2026-04-29T14:05:09+00:00\",\"description\":\"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196; HKG: 2196) reported Q1 2026 financial results showing RMB 10.073 billion (USD 1.47 billion) in revenue, representing 6.93% year-over-year (YOY) growth, while net profit attributable to shareholders (excluding non-recurring items) surged 21.96% YOY to RMB 501 million (USD 73.3 million).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64256#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64256\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64256#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2908.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2908.webp\",\"width\":1080,\"height\":608,\"caption\":\"Fosun Pharma Reports Strong Q1 2026 Results with 22% Profit Growth and Robust Pipeline Advancement\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64256#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fosun Pharma Reports Strong Q1 2026 Results with 22% Profit Growth and Robust Pipeline Advancement\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Fosun Pharma Reports Strong Q1 2026 Results with 22% Profit Growth and Robust Pipeline Advancement - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196; HKG: 2196) reported Q1 2026 financial results showing RMB 10.073 billion (USD 1.47 billion) in revenue, representing 6.93% year-over-year (YOY) growth, while net profit attributable to shareholders (excluding non-recurring items) surged 21.96% YOY to RMB 501 million (USD 73.3 million).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64256","og_locale":"en_US","og_type":"article","og_title":"Fosun Pharma Reports Strong Q1 2026 Results with 22% Profit Growth and Robust Pipeline Advancement","og_description":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196; HKG: 2196) reported Q1 2026 financial results showing RMB 10.073 billion (USD 1.47 billion) in revenue, representing 6.93% year-over-year (YOY) growth, while net profit attributable to shareholders (excluding non-recurring items) surged 21.96% YOY to RMB 501 million (USD 73.3 million).","og_url":"https:\/\/flcube.com\/?p=64256","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-29T14:05:08+00:00","article_modified_time":"2026-04-29T14:05:09+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2908.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64256#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64256"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Fosun Pharma Reports Strong Q1 2026 Results with 22% Profit Growth and Robust Pipeline Advancement","datePublished":"2026-04-29T14:05:08+00:00","dateModified":"2026-04-29T14:05:09+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64256"},"wordCount":368,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=64256#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2908.webp","keywords":["Finanical Reports","Fosun Pharmaceutical","HKG: 2196","SHA: 600196"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64256#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64256","url":"https:\/\/flcube.com\/?p=64256","name":"Fosun Pharma Reports Strong Q1 2026 Results with 22% Profit Growth and Robust Pipeline Advancement - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=64256#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=64256#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2908.webp","datePublished":"2026-04-29T14:05:08+00:00","dateModified":"2026-04-29T14:05:09+00:00","description":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196; HKG: 2196) reported Q1 2026 financial results showing RMB 10.073 billion (USD 1.47 billion) in revenue, representing 6.93% year-over-year (YOY) growth, while net profit attributable to shareholders (excluding non-recurring items) surged 21.96% YOY to RMB 501 million (USD 73.3 million).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64256#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64256"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=64256#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2908.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2908.webp","width":1080,"height":608,"caption":"Fosun Pharma Reports Strong Q1 2026 Results with 22% Profit Growth and Robust Pipeline Advancement"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64256#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Fosun Pharma Reports Strong Q1 2026 Results with 22% Profit Growth and Robust Pipeline Advancement"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2908.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64256","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64256"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64256\/revisions"}],"predecessor-version":[{"id":64259,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64256\/revisions\/64259"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/64258"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64256"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64256"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64256"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}